Screener
Pacific Biosciences of California PACB Business Segments — Impairment Charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAndIntangibleAssetImpairment.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
| (In thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 23,022 | 22,529 | 42,630 | 51,582 |
| Sales and marketing | 18,492 | 19,516 | 34,270 | 39,592 |
| General and administrative | 14,901 | 16,659 | 30,276 | 36,751 |
| Impairment charges | — | — | — | 15,000 |
| Settlement charges | — | — | 15,400 | — |
| Gain on disposal of assets | — | — | (45,796) | — |
| Change in fair value of contingent consideration | — | — | — | (18,700) |
| Amortization of acquired intangible assets | 833 | 833 | 1,666 | 362,875 |
Item 1. Financial Statements (unaudited):
FAQ
- What is Pacific Biosciences of California's business segments — impairment charges?
- Pacific Biosciences of California (PACB) reported business segments — impairment charges of $0 in Q2 2026.
- What does business segments — impairment charges mean?
- This represents non-cash charges recognized when the carrying value of an asset, such as goodwill or long-lived assets, exceeds its fair value. These charges indicate a reduction in the expected future economic benefit of specific investments or acquisitions.
Ask your AI about Pacific Biosciences of California's business segments — impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude